Considerable research is aimed at determining the mechanisms by which hormone-refractory prostate cancer develops. In an effort to assist in the under-standing of recurrent prostate cancer and the cellular processes that mediate this disease, a mathematical model is presented that describes both the pretreat-ment growth and the posttherapy relapse of human prostate cancer xenografts. Our goal is to evaluate the interplay between the multiple mechanisms that have been postulated as causes of androgen-independent relapse. Simulations of the model show that molecular events that render the androgen receptor irrelevant to disease progression, such as upregulation of BCL2, can result in relapse after androgen deprivation therapy. However, decrea...
Since the Nobel Prize-winning work of Huggins, androgen ablation has been a mainstay for treatment o...
CONTEXT: Androgen deprivation therapy (ADT) is the backbone of treatment for advanced prostate cance...
<div><p>Almost all prostate cancers respond to androgen deprivation treatment but many recur. We pos...
AbstractConsiderable research is aimed at determining the mechanisms by which hormone-refractory pro...
textabstractBackground: Prostate cancer is initially dependent on androgens for survival and growth,...
Prostate cancer is the most frequently diagnosed non-cutaneous malignancy and second leading cause o...
Androgen ablation is the standard treatment for advanced disease. Despite initial success, approxima...
abstract: Predicting the timing of a castrate resistant prostate cancer is critical to lowering medi...
PURPOSE:To discuss the role of membrane androgen receptors and to investigate the potential role of ...
textabstractProstate cancer has a high incidence in the western world. Early detection of the disea...
abstract: Background Androgens bind to the androgen receptor (AR) in prostate cells and are essentia...
Prostate cancer (PCa) is today the second most common cancer in the world, with almost 400,000 death...
Prostate cancer (CaP) is the leading cause of cancer in men affecting 24,700 Canadians each year and...
Prostate cancer co-opts a unique set of cellular pathways in its initiation and progression. The het...
Abstract: Prostate cancer is the most commonly diagnosed nonskin cancer and the second leading cause...
Since the Nobel Prize-winning work of Huggins, androgen ablation has been a mainstay for treatment o...
CONTEXT: Androgen deprivation therapy (ADT) is the backbone of treatment for advanced prostate cance...
<div><p>Almost all prostate cancers respond to androgen deprivation treatment but many recur. We pos...
AbstractConsiderable research is aimed at determining the mechanisms by which hormone-refractory pro...
textabstractBackground: Prostate cancer is initially dependent on androgens for survival and growth,...
Prostate cancer is the most frequently diagnosed non-cutaneous malignancy and second leading cause o...
Androgen ablation is the standard treatment for advanced disease. Despite initial success, approxima...
abstract: Predicting the timing of a castrate resistant prostate cancer is critical to lowering medi...
PURPOSE:To discuss the role of membrane androgen receptors and to investigate the potential role of ...
textabstractProstate cancer has a high incidence in the western world. Early detection of the disea...
abstract: Background Androgens bind to the androgen receptor (AR) in prostate cells and are essentia...
Prostate cancer (PCa) is today the second most common cancer in the world, with almost 400,000 death...
Prostate cancer (CaP) is the leading cause of cancer in men affecting 24,700 Canadians each year and...
Prostate cancer co-opts a unique set of cellular pathways in its initiation and progression. The het...
Abstract: Prostate cancer is the most commonly diagnosed nonskin cancer and the second leading cause...
Since the Nobel Prize-winning work of Huggins, androgen ablation has been a mainstay for treatment o...
CONTEXT: Androgen deprivation therapy (ADT) is the backbone of treatment for advanced prostate cance...
<div><p>Almost all prostate cancers respond to androgen deprivation treatment but many recur. We pos...